Predictors of 5 Year Survival Rate in Hepatocellular Carcinoma Patients

Overview

Journal J Res Med Sci

Specialty General Medicine

Date 2019 Nov 20

PMID 31741658

Citations 60

Authors

Arash Sarveazad

Shahram Agah

Asrin Babahajian

Naser Amini

Mansour Bahardoust

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common primary hepatic malignancies and growing challenges of global health. In this study, for the first time in Iran, we investigated the 5-year survival rate and prognostic factors in patients with HCC.

Materials And Methods: In this historical cohort study, we examined the medical records of 227 HCC patients who were registered in the central tumor registry of our institution from September 2007 to September 2017. Demographic data, clinical parameters, received treatments, and survival curves from time of diagnosis were evaluated. Kaplan-Meier was used for univariate analysis, and multivariable analysis was performed by Cox regression.

Results: A total of 208 (91.63%) patients were dead. The 5-year survival rate was estimated 19 (8.37%). The average follow-up in this study was 14.3 months. Overall median survival rate was 12.1 months. Univariate analysis showed that tumor size, metastasis, number of involved lymph node, hepatitis type, and treatment were significantly related to the survival rate, and Cox regression analysis revealed that the tumor size >3 cm (hazard ratio [HR] = 3.06, 95% confidence interval [CI] = 1.68-4.97; = 0.027), involved lymph nodes >2 (HR = 4.12, 95% CI = 2.66-6.38; = 0.001), metastasis (HR = 3.87, 95% CI = 3.13-6.54; = 0.011), combination therapy with surgery and chemotherapy (HR = 0.4, 95% CI = 0.15-0.79; = 0.023), and coinfection with hepatitis B virus and hepatitis C virus (HR = 2.11, 95% CI = 1.81-4.6; = 0.036) are the most relevant prognostic factors with 5-year survival rate in patients with HCC.

Conclusion: Results of this study will help estimate survival rates for patients with HCC according to their clinical status.

Citing Articles

Development of a self-management behavior assessment scale for liver cancer patients from ethnic minorities.

Liu B, Chen J, Zhao X, Gui Q, Lin Y, He B BMC Health Serv Res. 2025; 25(1):315.

PMID: 40001076 PMC: 11863450. DOI: 10.1186/s12913-025-12272-0.

Effect of surgery on overall survival and cancer-specific survival in patients with primary HCC: A study based on PSM in the SEER cohort.

Xia L, Yu S, Bai Y, Liang X, Wu F, Gao Y Medicine (Baltimore). 2025; 104(8):e41521.

PMID: 39993067 PMC: 11857015. DOI: 10.1097/MD.0000000000041521.

AKT activation participates in Fascin-1-induced EMT in hepatoma cells.

Zhao P, Ai K, Li Y, Cheng W, Yang J Cytotechnology. 2025; 77(2):46.

PMID: 39867827 PMC: 11759734. DOI: 10.1007/s10616-025-00707-9.

Durable Response to Combined Nivolumab, Lenvatinib, and Radiation Therapy Against Oligometastatic Hepatocellular Carcinoma.

Chun S, Coyne E, Meyer J, Ho W Cureus. 2024; 16(11):e73434.

PMID: 39669840 PMC: 11634549. DOI: 10.7759/cureus.73434.

Discovery of novel and highly potent dual-targeting PKMYT1/HDAC2 inhibitors for hepatocellular carcinoma through structure-based virtual screening and biological evaluation.

Yang Y, Wang Y, Chen J, Niu M, Wang Y, Jin X Front Pharmacol. 2024; 15:1491497.

PMID: 39619613 PMC: 11604427. DOI: 10.3389/fphar.2024.1491497.

References

Kim J, Choi M, Lee H, Kim D, Lee J, Koh K . Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol. 2006; 21(3):588-94. DOI: 10.1111/j.1440-1746.2005.04127.x. View

Kubicka S, Rudolph K, Hanke M, Tietze M, Tillmann H, Trautwein C . Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver. 2000; 20(4):312-8. DOI: 10.1034/j.1600-0676.2000.020004312.x. View

Franceschi S, Raza S . Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett. 2008; 286(1):5-8. DOI: 10.1016/j.canlet.2008.10.046. View

Caselitz M, Masche N, Flemming P, Stern C, Manns M, Wagner S . [Prognosis of hepatocellular carcinoma according to new staging classifications]. Dtsch Med Wochenschr. 2004; 129(33):1725-30. DOI: 10.1055/s-2004-829023. View

Rabe C, Pilz T, Klostermann C, Berna M, Schild H, Sauerbruch T . Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol. 2002; 7(2):208-15. PMC: 4723524. DOI: 10.3748/wjg.v7.i2.208. View

Dohmen K, Shirahama M, Shigematsu H, Irie K, Ishibashi H . Optimal treatment strategy for elderly patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2004; 19(8):859-65. DOI: 10.1111/j.1440-1746.2003.03306.x. View

Allgaier H, Deibert P, Olschewski M, Spamer C, Blum U, Gerok W . Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients. Int J Cancer. 1998; 79(6):601-5. DOI: 10.1002/(sici)1097-0215(19981218)79:6<601::aid-ijc8>3.0.co;2-f. View

Weinmann A, Koch S, Niederle I, Schulze-Bergkamen H, Konig J, Hoppe-Lotichius M . Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. J Clin Gastroenterol. 2013; 48(3):279-89. DOI: 10.1097/MCG.0b013e3182a8a793. View

Montomoli J, Erichsen R, Norgaard M, Hoyer M, Hansen J, Jacobsen J . Survival of patients with primary liver cancer in central and northern Denmark, 1998-2009. Clin Epidemiol. 2011; 3 Suppl 1:3-10. PMC: 3144772. DOI: 10.2147/CLEP.S20623. View

10.

Weishaupt N, Blesch A, Fouad K . BDNF: the career of a multifaceted neurotrophin in spinal cord injury. Exp Neurol. 2012; 238(2):254-64. DOI: 10.1016/j.expneurol.2012.09.001. View

11.

Otto G, Heuschen U, Hofmann W, Krumm G, Hinz U, Herfarth C . Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 1998; 227(3):424-32. PMC: 1191281. DOI: 10.1097/00000658-199803000-00015. View

12.

Fujii H, Itoh Y, Ohnishi N, Sakamoto M, Ohkawara T, Sawa Y . Factors associated with the overall survival of elderly patients with hepatocellular carcinoma. World J Gastroenterol. 2012; 18(16):1926-32. PMC: 3337568. DOI: 10.3748/wjg.v18.i16.1926. View

13.

Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F . Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol. 2007; 102(8):1661-70. DOI: 10.1111/j.1572-0241.2007.01337.x. View

14.

Zeeneldin A, Eid Salem S, Darwish A, El-Gammal M, Hussein M, Saadeldin M . Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors. J Hepatocell Carcinoma. 2016; 2:3-9. PMC: 4918279. DOI: 10.2147/JHC.S73828. View

15.

Selcuk H . Prognostic Factors and Staging Systems in Hepatocellular Carcinoma. Exp Clin Transplant. 2017; 15(Suppl 2):45-49. DOI: 10.6002/ect.TOND16.L11. View

16.

Tandon P, Garcia-Tsao G . Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009; 29(4):502-10. PMC: 2711257. DOI: 10.1111/j.1478-3231.2008.01957.x. View

17.

Kirchner G, Kirovski G, Hebestreit A, Scholmerich J, Schlitt H, Stoeltzing O . Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany. Int J Clin Exp Med. 2010; 3(2):169-79. PMC: 2894652. View

18.

Wang Z, Gu X, Thrift A . Factors associated with favorable survival outcomes for Asians with hepatocellular carcinoma: A sequential matching cohort study. PLoS One. 2019; 14(4):e0214721. PMC: 6447218. DOI: 10.1371/journal.pone.0214721. View

19.

Abbas Z, Siddiqui A, Luck N, Hassan M, Mirza R, Naqvi A . Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. J Pak Med Assoc. 2008; 58(11):602-7. View

20.

Tunissiolli N, Castanhole-Nunes M, Pavarino E, da Silva R, Silva R, Goloni-Bertollo E . Clinical, Epidemiological and Histopathological Aspects in Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation. Asian Pac J Cancer Prev. 2018; 19(10):2795-2802. PMC: 6291045. View